Moderna

FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder(Reuters) - Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc (MRNA.O), fell about 10% on Wednesday, as investor concerns grew about the prospects of…

This story is available exclusively on Business Insider Prime. Join BI Prime and start reading now. The biotech Moderna has skyrocketed to global prominence, leading the world's race for a coronavirus vaccine.The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven,…

New York (CNN Business)Moderna's stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine. As ordinary investors piled …

Skeptics are questioning the biotech's recent coronavirus vaccine-related announcements. What happened Shares of Moderna (NASDAQ:MRNA) fell nearly 9% on Thursday, continuing a downward trend that began soon after the biotechnology company's recent stock sale. So what  Moderna's stock soared on Monday after it released positive data from its phase 1 study for mRNA-1273, its coronavirus vaccine…

The former pharmaceutical executive leading the White House’s coronavirus vaccine effort is divesting from vaccine developer Moderna Inc., the biotech company said Monday after early-stage test results sent its stock soaring. Moncef Slaoui resigned from Moderna’s board of directors when the Trump administration tapped him last week to be chief advisor for its Operation Warp…